Clinical course of Covid-19 in a cohort of patients with Behçet disease

Correa‐Rodríguez, María; Callejas-Rubio, José-Luis; Rueda‐Medina, Blanca; Ríos-Fernández, Raquel; Fernández, Javier de la Hera; Centeno, Ortego

doi:10.1016/j.medcli.2021.11.009

Cited by 5 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Table IV we present an overview of the current literature on BD and COV-ID-19. We have added 4 studies which also used a sample survey (23)(24)(25)(26). In total 2014 BD patients were discussed in these studies, 313 patients were tested positive.…”

Section: Discussionmentioning

confidence: 99%

Clinical course of COVID-19 infections in patients with Behçet's disease in the Netherlands

Otter¹,

Houwen²,

Hagen³

et al. 2021

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

The aim of this study is to investigate the cumulative incidence and the severity of COVID-19 infections in patients with Behçet's disease. MethodsA retrospective cohort study of patients with Behçet's disease was conducted. We obtained the data systematically from electronic patient files and through telephone interviews between February 2020 and May 1, 2021. Main outcomes were COVID-19 infection, disease duration, hospitalisation, intensive care admission and mortality. Secondary outcome was adherence to quarantine measures as recommended by the government.Results 185 Behçet's disease patients were included (mean age 42.2 years, 54% female); 58% of the patients were receiving colchicine, 30% anti-TNFα, 16% azathioprine and 8% systemic steroids. 30 patients (16.2%) were positive for COVID-19. Within our cohort, the cumulative incidence of COVID-19 was therefore 16.2% (95% CI 11.2% -22.3%), which is significantly increased when compared to the general Dutch population (8.7% (95% CI 8.72% -8.73%)) (p < 0.001). Four out of 30 (13%) patients were admitted to the hospital. There was no COVID-19 related mortality observed. Patients adhered to government measures; except in the period between the 1 st of June and the 28 th of September, this cohort received more visitors than in period 1 and 3. ConclusionIn this cohort, Behçet's disease patients have a higher risk for COVID-19 infection, without an increase of virus-related mortality. The course of COVID-19 disease in this cohort is relatively mild, with a lower admission rate than expected of patients using immunosuppressive medication.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical course of COVID-19 infections in patients with Behçet's disease in the Netherlands

Otter¹,

Houwen²,

Hagen³

et al. 2021

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

show abstract

“…A number of cohort studies and case series from Turkey, USA, Spain, Iran and Italy reported the incidence and outcome of BS patients with COV-ID-19 (81)(82)(83)(84)(85)(86)(87)(88). Although the incidence of COVID-19 was increased compared to the general population, the outcome was mild with no increased mortality or thrombotic events.…”

Section: Covid-19mentioning

confidence: 99%

Behçet's syndrome: one year in review 2022

Hatemi

Seyahi

Fresko

et al. 2022

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

This review highlights publications on different aspects of Behçet's syndrome (BS) that appeared in 2021 and provides a critical view. These publications include works on the epidemiology of BS across different continents, newly developed instruments to assess damage in BS, studies highlighting the immunopathogenesis, genetics and epigenetic factors, histopathology of the pathergy lesion, clinical and imaging aspects of vascular involvement, and safety and efficacy of therapeutic agents including tocilizumab, apremilast and direct oral anticoagulants.

show abstract

“…However, underreporting of COVID-19 in ABD patients is possible, especially in asymptomatic cases. 3 In addition, in case series from Spain, 4 Italy, 5 the Netherlands, 6 Turkey 7-9 and Iran 10 lower hospitalization, intensive care and death rates of COVID-19-infected ABD patients were observed in 2021/2022, when compared to those in 2020 (Table 2). Our only hospitalized patient has also been infected in 2020.…”

mentioning

confidence: 96%